ClinicalTrials.gg

Lupus Erythematosus, Systemic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,211 studies for Lupus Erythematosus, Systemic across more than 10 countries. 406 are recruiting or about to start. 921 of them are mainly about Lupus Erythematosus, Systemic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its narrower condition Lupus Nephritis too: 1,432 studies, 483 open.

ClinicalTrials.gov finds 1,511 studies for Lupus Erythematosus, Systemic. How that becomes 1,210 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Lupus Erythematosus, Systemic, and those it files under no condition that list Lupus Erythematosus, Systemicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,511Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −215Filed under a narrower condition, counted on its own pageLupus Nephritis 215
  3. −10List Lupus Erythematosus, Systemic as a condition, but the registry did not file them under itMost often written as “Juvenile Systemic Lupus Erythematosus” (3), “Neuropsychiatric Systemic Lupus Erythematosus” (1), and “Bullous Systemic Lupus Erythematosus” (1). The registry filed them under other conditions only, most often Dermatomyositis (2) and Arthritis, Juvenile (2).
  4. −76Match it another way61 name it in the title and 15 by a synonym or other text the search reads.
  5. 1,210The count on this page22 of them list Lupus Erythematosus, Systemic in their own words; the registry filed them under no condition.

Status

Completed
478
Recruiting
284
Status unknown
119
Not yet recruiting
103
Terminated
87
Active, not recruiting
70

Phase

Phase 1
290
Phase 2
273
Phase 3
125
Phase 4
58
Early Phase 1
46

Where

United States
477
China
266
France
168
Spain
144
Germany
125
Poland
112

Who develops what

Add Lupus Erythematosus, Systemic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 102 programs from 72 companies, 74 with this as their studies’ main aim; 7 with a live phase 3 study; 16 primary completions in the next 12 months. Compare Bristol-Myers Squibb, AstraZeneca and Chongqing Precision Biotech here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CyclophosphamideRecent, repeated
Evidence
  • NCT07015983 · Bristol-Myers Squibb · Phase 2 · live · background · “Cyclophosphamide” · registered May 2025
  • NCT06897930 · AstraZeneca · Phase 2 · live · background · “Cyclophosphamide” · registered Mar 2025
  • NCT00626197 · Hoffmann-La Roche · Phase 3 · background · “Cyclophosphamide” · registered Feb 2008
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07015983 · Bristol-Myers Squibb · Phase 2 · live · background · “Fludarabine” · registered May 2025
  • NCT06897930 · AstraZeneca · Phase 2 · live · background · “Fludarabine” · registered Mar 2025
Beijing Biotech18% of its industry studies22 studies

7 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
cenerimod☆ Track4 live phase-3 studies: NCT05672576, NCT05648500, NCT06475742Viatris Inc.
anifrolumabApproved: US 2021 · EU 2022☆ Track6 live phase-3 studies: NCT07430306, NCT07691970, NCT05138133AstraZeneca
dapirolizumab pegol☆ Track2 live phase-3 studies: NCT04976322, NCT06617325UCB S.A.
Anti-CD20 Monoclonal Antibody MIL62☆ Track1 live phase-3 study: NCT07405970Beijing Mabworks Biotech Co., Ltd.
nipocalimabApproved: US 2025 · EU 2025☆ Track1 live phase-3 study: NCT07438496Johnson & Johnson

The 5 in phase 3 with the nearest primary completion, of 102 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (16)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.VENT-03 · Ventus Therapeutics U.S., Inc. · Phase 2 named, not the main aimNCT07260877 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus — primary endpoint: Evaluate the effect of VENT-03 on the interferon gene signature in the skin · 24 enrolled
  • Dec 2026 est.BTK Inhibitor TQB3702 · Sino Biopharmaceutical Limited · Phase 2 main aimNCT06859931 Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE) — primary endpoint: SLE response index -4 (SRI-4) · 120 enrolled
  • 31 Dec 2026 est.cenerimod · Viatris Inc. · Phase 3 main aimNCT05672576 A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus — primary endpoint: Response on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 12 compared to baseline · 451 enrolled

13 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lupus Erythematosus, Systemic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 6 open · Antimetabolites 4 open · Alkylating agents 4 open · JAK inhibitors 3 open · Corticosteroids 2 open

Coming up

128studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger. 54 (19%) take children under 18. 14 (5%) are for women only and 0 (0%) for men only; 32 (11%) take healthy volunteers.

Recruiting studies that take each age, of 284
AgeWomenMen
1037 (13%)34 (12%)
18271 (95%)258 (91%)
30267 (94%)253 (89%)
40266 (94%)252 (89%)
50266 (94%)254 (89%)
65245 (86%)235 (83%)
75151 (53%)143 (50%)
85114 (40%)106 (37%)

Across all 1,211 studies, recruiting or not: 53% stop at 75 or younger and 31% at 65; 18% take children; 9% are for women only and 1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lupus Erythematosus, Systemic studies take

Of 147 phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 128 mo16–36 · 147 studies28 mo13–35 · 108 studies—
Phase 1/242 mo21–60 · 38 studies——
Phase 236 mo27–55 · 95 studies32 mo25–47 · 67 studies—
Phase 351 mo38–84 · 53 studies——
Phase 433 mo30–42 · 33 studies——
Interventional, no phase23 mo10–38 · 130 studies—23 mo10–38 · 123 studies
Observational64 mo30–126 · 112 studies—59 mo25–212 · 90 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,211. Browse all 1,211 → or search them.